- Home
- RCUS
as 11-21-2024 10:38am EST
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $34.50 | AVG Volume (30 days): | 835.5K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.50 - $20.31 | Next Earning Date: | 11-06-2024 |
| Revenue: | $263,000,000 | Revenue Growth: | 119.17% |
| Revenue Growth (this year): | 112.97% | Revenue Growth (next year): | -15.39% |
Latest Arcus Biosciences Inc. News
RCUS Breaking Stock News: Dive into RCUS Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Argus Research
9 days ago
RCUS: Raising target price to $18.00
Business Wire
9 days ago
Arcus Biosciences Announces New Employment Inducement Grants
Simply Wall St.
12 days ago
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report
GuruFocus.com
14 days ago
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
Zacks
15 days ago
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
15 days ago
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Argus Research
16 days ago
RCUS: Lowering target price to $16.00
Compare RCUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.